Literature DB >> 1495662

Benzodiazepine use in general practice--is it a problem?

D A North1, B R McAvoy, A M Powell.   

Abstract

AIMS: The aim of this study was to describe benzodiazepine use in a general practice.
METHODS: A prevalence study in an Auckland general practice was undertaken to describe the benzodiazepines prescribed, patterns of use and compliance. An associated case control study compared benzodiazepine users and nonusers.
RESULTS: The age standardised prevalence rate of benzodiazepine use in this Auckland general practice was 3.4% for patients over 20 years of age. The benzodiazepine users described were predominantly elderly (70% over 60 years of age) and female (62.5%). They had significantly more medical and psychiatric complaints than matched controls. Triazolam and diazepam accounted for 60.9% of the benzodiazepines prescribed. Over one-third of the patients using benzodiazepines were concurrently prescribed other psychotropic medications, primarily tricyclic antidepressants.
CONCLUSION: This rate suggests an overall decline in benzodiazepine use since previous studies. Benzodiazepines continue to be prescribed predominantly in the elderly, a group at considerable risk from side effects. Doctors should continue to inform their patients about the side effects of benzodiazepines, the risks of dependence and difficulties of withdrawal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495662

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  3 in total

1.  Heart failure in primary care.

Authors:  A McElhinney
Journal:  Br J Gen Pract       Date:  1996-06       Impact factor: 5.386

2.  Benzodiazepines: more "behavioural" addiction than dependence.

Authors:  Carlos de las Cuevas; Emilio Sanz; Juan de la Fuente
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

3.  High daily doses of benzodiazepines among Quebec seniors: prevalence and correlates.

Authors:  M Y Egan; C Wolfson; Y Moride; J Monette
Journal:  BMC Geriatr       Date:  2001       Impact factor: 3.921

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.